BPC-157, TB-500, IGF-1 LR3 & PEG-MGF: Peptides for Muscle & Tendon Recovery Explained
A host-led overview of BPC-157, TB-500, IGF-1 LR3 and PEG-MGF for muscle and tendon injuries, with anecdotal doses, a phased rehab framework and repeated warnings about weak human evidence.
With Ultimate Biohacker 10X (Says they are a doctor, no degree stated)
Key moments
Tap a moment to play the video from there.
- 0:00Show intro and the injury scenarioThe host introduces the podcast and describes a torn-muscle scenario to set up why recovery peptides are getting attention.
- 1:33Reality check on evidence and legalityThe host says the evidence is preclinical, that the compounds are not FDA approved for this use, and that WADA bans them. A disclaimer follows, with advice to get a physician and verified sourcing.
- 2:42Three phases of injury healingThe host walks through inflammation, proliferation and remodeling, and says peptides signal the body but do not replace loading, sleep, nutrition or time.
- 4:30BPC-157 and tendon repairThe host describes preclinical results, a small human knee series, a 4 to 6 hour half-life and an anecdotal dose of 250 to 500 micrograms a day.
- 6:04TB-500 and the combined stackThe host describes TB-500 as a thymosin beta 4 fragment with a longer half-life and anecdotal dosing of 2.5 to 5 mg a week. They explain the idea that TB-500 recruits cells and BPC-157 directs them.
- 8:50IGF-1 LR3 for muscleThe host describes IGF-1 LR3 as a long-acting growth factor analog with a 20 to 30 hour half-life. They flag low blood sugar and a caution for people with cancer history.
- 9:47PEG-MGF as an add-onThe host describes pegylated MGF as a satellite cell activator and suggests introducing it from week three, after the BPC and TB base.
- 10:58Phased rehab protocolThe host sets out acute, repair and remodeling phases, then nutrition, sleep and the progression from isometrics to eccentrics.
- 12:41Risks, legality and sourcingThe host covers reported side effects, WADA and FDA status, certificates of analysis, bacteriostatic water and red flags when buying.
- 14:47Future directions and recapThe host mentions copper peptides, targeted delivery and personalized genetic protocols, then recaps four pillars and says rehab comes first.
What the video says
This episode of The Human 5.0 Project, a biohacking podcast, is hosted by someone who goes by Ultimate Biohacker 10X. It covers four peptides the host links to muscle and tendon recovery: BPC-157, TB-500, IGF-1 LR3 and PEG-MGF. The host opens with a reality check. They say these are research compounds, not FDA approved for human use or injury treatment, that the evidence is preclinical and weak in humans, and that the World Anti-Doping Agency has banned them.
After a short primer on the three phases of injury repair (inflammation, proliferation and remodeling), the host takes each peptide in turn. BPC-157 is described as a tendon-focused peptide. The host cites preclinical studies showing better collagen organization, and one small retrospective series on knee injection in which about seven of 12 patients reported pain relief. TB-500 is described as a longer-lasting, more systemic fragment of thymosin beta 4. The host calls the two together the core stack and says that rests on anecdotal and community reporting. IGF-1 LR3 and PEG-MGF are presented as optional add-ons for muscle, with human data the host calls mechanistic or limited. Anecdotal doses are given for each, and the host attaches them to a research-use framing.
The host then lays out a three-phase framework: an acute phase in weeks one to two, a repair phase in weeks three to six, and a remodeling phase from week seven with the peptides tapered. They stress that rehab comes first, moving from isometrics to eccentrics to full strength. They also name protein intake, collagen with vitamin C, sleep and micronutrients as non-negotiable. The host says users report a 30 to 50% faster return to baseline, but says no one can separate the peptide from rehab and placebo without controlled human trials.
The last section covers risks, legality and sourcing. The host lists mostly mild reported side effects, blood sugar changes and a cancer-history caution for IGF-1 LR3, the WADA categories, and the gray market. They advise a third-party certificate of analysis showing purity above 98%, and describe reconstitution with bacteriostatic water. The episode closes with a brief look at copper peptides, targeted delivery and personalized genetic protocols as possible future directions.
On each compound
BPC-1574:30
The host calls BPC-157 a tendon specialist and cites preclinical studies of faster repair with better collagen organization. They say human evidence is thin, giving an anecdotal range of 250 to 500 micrograms a day by subcutaneous injection near the injury.
See how your DNA reads BPC-157TB-5006:04
According to the host, TB-500 is a synthetic fragment of thymosin beta 4 that regulates actin and cell migration, with a half-life of around 4 to 6 days. They say human trials exist for other tissues but none for tendon recovery, and give an anecdotal 2.5 to 5 mg a week.
See how your DNA reads TB-500IGF-1 LR38:50
The host describes IGF-1 LR3 as a long-acting analog tied to protein synthesis and satellite cell activity. They say there are no direct injury trials of the LR3 variant, mention an anecdotal 40 to 80 micrograms a day, and warn about hypoglycemia and cancer history.
See how your DNA reads IGF-1 LR3PEG-MGF9:47
The host describes pegylated MGF as a longer-lasting form of a splice variant of IGF-1 that activates satellite cells after mechanical stress. They say human data is mechanistic only and cite an anecdotal 200 to 400 micrograms two to three times a week, injected into the target muscle.
See how your DNA reads PEG-MGF“Anecdotes are compelling, but anecdotes are not randomized controlled trials.”
What this video doesn’t settle
- The host says the doses and protocols are anecdotal or community-reported, so the video does not establish an effective or safe dose for any of the four peptides.
- The claimed 30 to 50% faster return to baseline has no control group, and the host says it cannot be separated from rehab or placebo.
- The video offers no human trial evidence for IGF-1 LR3 or PEG-MGF in injury recovery, and the host calls their human data mechanistic or limited.
Questions this video answers
Is there human evidence that BPC-157 helps tendon injuries?
The host says human evidence is thin. They cite one small retrospective series on knee injection in which about seven of 12 patients reported pain relief, and say there is no large randomized human trial for tendon or muscle injuries.
What is the BPC-157 and TB-500 stack?
The host describes it as a combination used in biohacker communities, nicknamed the Wolverine stack. They say TB-500 recruits cells and BPC-157 directs them to build, and that this rests on anecdotal and community reporting rather than trials.
What does the video say about sourcing and legality of recovery peptides?
The host says the compounds are not FDA approved for this use and are prohibited by WADA. On sourcing, they call the market gray and say to require a third-party certificate of analysis from HPLC or MS testing showing purity above 98%.
What side effects does the host mention for these peptides?
The host says most reported side effects are mild, such as injection site reactions, temporary fatigue, occasional GI upset with BPC-157, and blood sugar changes with IGF-1. They add that infection from poor hygiene is a rarer risk and that long-term effects are unknown.
How does the host say peptides fit with rehab?
The host says rehab comes first and peptides only amplify signals. They outline acute, repair and remodeling phases, with loading moving from isometrics to eccentrics, and say a bad rehab protocol can cancel out any benefit.
Video by The Human 5.0 Project on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
